This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Reyes, M. P. Articles by Kloner, R. A. Search for Related Content PubMed Articles by Reyes, M. P. Articles by Kloner, R. A. Social Bookmarking                         What's this?

Prolonged Captopril Therapy in Murine Viral Myocarditis

Division of Infectious Diseases, Wayne State University, Detroit, Michigan

Riad Khatib

St. John Hospital, Detroit, Michigan

Ghada Khatib

Grace Hospital, Detroit, Michigan

K.L. Ho

Henry Ford Hospital, Detroit, Michigan

Frederic Smith

Division of Infectious Diseases, Wayne State University, Detroit, Michigan

Robert A. Kloner

The Heart Institute, University of California, Los Angeles, California

Background: Acute myocarditis can progress to chronic heart muscle disease and cardiomyop athy. In the coxsackievirus B ₃ (CB₃) mouse model of myocarditis, early administration of cap topril, an angiotensin-converting enzyme (ACE) inhibitor, ameliorated histopathological changes in inflammation, necrosis, and calcification and reduced heart weight. Late administra tion of captopril reduced heart weight but did not affect the histological findings. In this study, we investigated the effects of prolonged captopril treatment in the chronic phase of this model.

Methods and Results: Three-week-old male CD₁ mice were infected with CB₃ and then randomized to receive placebo or captopril starting on day 7 of infection. Captopril, 2 g/L, was given as the drinking water daily for up to 6 months. Autopsies were performed at 6 and 10 months. Heart-to-body weight ratios were obtained, and deaths were tallied. Myocardial fibrosis was graded according to a score system. In addition, picrosirius red stain (PSR) also was used for assessment of collagen deposition. Mean heart weights were similar in both groups. Mean body weight was significantly lower in captopril-treated mice (40.7 g) than in the untreated group (43.6 g) at 6 months (P = .0155), and mortality was higher (8.7 vs 0.87%; P = .009). At 6 months, the mean myocardial fibrosis score in treated mice (0.12) was significantly less than in untreated animals (0.35; P = .035). With PSR, the mean myo cardial fibrosis score in the captopril group (1.20) was also significantly less than in the untreated group (1.58; P = .045). At 10 months, fibrosis scores were similar in both groups.

Conclusions: Chronic captopril treatment in CB₃ myocarditis reduces myocardial fibrosis.

Key Words: chronic heart muscle disease • mouse cardiomyopathy • ACE inhibitors • viral cardiomyopathy.

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 3, No. 1, 43-49 (1998)
DOI: 10.1177/107424849800300106


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. S. Leon, K. Wang, and D. M. Engman Captopril Ameliorates Myocarditis in Acute Experimental Chagas Disease Circulation, May 6, 2003; 107(17): 2264 - 2269. [Abstract] [Full Text] [PDF]